Teva TEVA NYSE · Healthcare · Israel
$44.01 +0.82% +$0.36
Summary
35 / 100 · Bulios Score
What speaks for it
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- Repaying its net debt would take 6.3 years of operating profit.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 2.9 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 100.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.7% a year over 5 years. Over the last 3 years it grew by 5.0% a year. For the next fiscal year analysts expect revenue to fall by 2.8%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 46 USD
- Research and development 6.0 USD
- Sales and administration 37 USD
- Taxes and other 7.6 USD
- Net profit 2.9 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD
Out of every 100 USD of revenue, 2.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 13.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 25
- Hold 20
- Sell 4
Today's price within the analysts' price targets
The average target of $47.33 is 7.5% above today's price. 51% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 85%
- Distribution Service 9.0%
- License 3.9%
- Product and Service, Other 2.5%
By region
- United States Segment 56%
- Europe Segment 31%
- International Markets 13%
Product brings in 85% of revenue. License grew fastest, by 43% a year.
Segments in detail